Vaccitech names Nadège Pelletier as chief scientific officer

The clinical-stage biopharma Vaccitech (Nasdaq:VACC) has appointed Nadège Pelletier as its new chief scientific officer. She will lead scientific teams in drug discovery and platform development at the company and will oversee its technical strategy.

Vaccitech is a UK-based biotech that develops vaccines and immunotherapies.

“It’s an exciting time to be joining Vaccitech,” Pelletier said in a news release.

Pelletier comes to Vaccitech with more than 15 years of experience in the pharma industry and academia.

Specializing in immunology and infectious diseases, she most recently worked as the senior principal scientist, autoimmunity, transplantation and inflammation at the Novartis Institutes for BioMedical Research (NIBR). At Novartis, Pelletier served as project leader in autoimmunity, inflammation and infectious diseases. She was accountable for building solid preclinical packages and developing biomarker strategies and translat…

Read more
  • 0